# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Calamity Jane (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI008-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ruth Ann Kessler, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

One-week review after outpatient withdrawal, seen the same day by addiction medicine. **S**

## History of present illness

Ms. Canary returns one week after intake and is seen by Dr. Two Bulls-Harmon of addiction medicine on the same day. Her last drink was on the morning of her intake visit. The clinic nurse saw or called her every day: her CIWA-Ar was 10 on the second day with tremor, sweats and poor sleep, then fell each day to 2 today. She took the five-day gabapentin schedule as written and finished it three days ago, had the three thiamine injections, and took the potassium for five days and the magnesium as prescribed. She has had no seizures, hallucinations or confusion. Her friend stayed close during the worst days. She is eating more. The intake tests showed no HIV or hepatitis C, no hepatitis B infection or immunity, a urine test with no opioids, fentanyl or other drugs, and a negative pregnancy test. The community health worker helped her apply for Medicaid and SNAP, and she has met the peer recovery specialist once. She would like to stay off alcohol completely and wants to know about medicines that help. **S**

| Element | Detail |
|---|---|
| Last drink | Morning of the intake visit, seven days ago |
| Withdrawal | CIWA-Ar highest 10 on day two; 2 today; no seizure, hallucinations or confusion |
| Gabapentin | Five-day schedule finished three days ago |
| Intake results | HIV and hepatitis C negative; hepatitis B not infected and not immune; urine test negative for opioids and fentanyl; pregnancy test negative |
| Benefits | Medicaid and SNAP applications submitted |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; appetite returning |
| Gastrointestinal | Negative | No vomiting, abdominal pain or black stools |
| Neurological | Negative | Tremor gone; no seizures, confusion or unsteadiness |
| Psychiatric | Positive | Low and restless in the evenings; cravings; no hallucinations; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Thiamine 100 mg oral tablet, one tablet daily **S**
- Folic acid 1 mg oral tablet, one tablet daily **S**
- Magnesium oxide 400 mg oral tablet, one tablet twice daily for two weeks **S**
- Naltrexone 50 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/82 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 50.4 kg; BMI 18.5 kg/m². All vital signs are synthetic.

Potassium: 3.9 mmol/L; Magnesium: 1.8 mg/dL. All results are synthetic.

## Change since baseline

- Potassium: 3.3 mmol/L (low) at baseline, 3.9 mmol/L at this visit **S**
- Magnesium: 1.5 mg/dL (low) at baseline, 1.8 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert; blood pressure 128/82, pulse 84, temperature 36.8 °C |
| Eyes | No nystagmus; no scleral icterus |
| Neurological | No tremor with arms outstretched; gait steady; oriented |
| Abdomen | Soft and non-tender; liver edge not palpable |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Alcohol withdrawal, mild** (F10.230). Withdrawal is over without complications after five days of gabapentin and daily checks. Potassium 3.9 and magnesium 1.8 are now normal. **S**
   - No further withdrawal medicine.
   - Magnesium oxide to finish next week; thiamine and folic acid continue.
2. **Severe alcohol use disorder, early in recovery** (F10.20). Dr. Two Bulls-Harmon agrees with severe alcohol use disorder (nine DSM-5-TR criteria) and recommends naltrexone, which can begin now that withdrawal is over and the urine test shows no opioids; her AST is under three times the upper limit. Safety reviewed: no thoughts of suicide or self-harm; the rifle is with her friend. **S**
   - Naltrexone 50 mg daily, with a wallet card explaining that it blocks opioid pain medicines.
   - A monthly extended-release injection if daily tablets prove hard.
   - Weekly peer recovery contact and a mutual-help meeting of her choice.
3. **Raised liver enzymes with a high FIB-4** (R74.01). FIB-4 3.93 at intake; elastography is the next step. **S**
   - Transient elastography at the four-week visit, after some weeks without alcohol.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Drinking since the last visit (her own account, day by day), cravings and triggers | Every visit | Completed today | No alcohol since the morning of intake; cravings in the evenings |
| Laboratory | PEth, explained as part of care and not as a test of honesty | At baseline and about every one to two months | Up to date | 820 ng/mL at intake; next at four weeks |
| Examination | Withdrawal (CIWA-Ar) and transfer criteria | Daily during withdrawal management | Completed today | Daily nurse checks for six days: highest 10 on day two, 2 today; no transfer needed |
| Laboratory | Thiamine, folate and electrolytes | Thiamine before glucose and through recovery; electrolytes rechecked within a week if low | Completed today | Three thiamine injections, then tablets; potassium 3.9 mmol/L and magnesium 1.8 mg/dL after replacement |
| Medication safety | Medicine for alcohol use disorder: adherence, side effects, opioid exposure | Every visit | Completed today | Naltrexone 50 mg started today; urine test negative for opioids and fentanyl; wallet card given |
| Laboratory | Liver enzymes on naltrexone | Baseline, within the first months of treatment, then periodically | Up to date | Baseline at intake: AST 96, ALT 44 U/L; recheck at four weeks |
| Imaging | Liver fibrosis: FIB-4, transient elastography, albumin, INR, platelets | Elastography when FIB-4 is above 2.67, repeated after months without alcohol | Ordered | FIB-4 3.93 at intake; transient elastography booked for the four-week visit |
| Examination | Weight, meals and food access | Every visit | Completed today | Weight 50.4 kg, up 0.4 kg; eating more; SNAP application submitted |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcohol | At baseline, after two to four weeks without alcohol, then at least monthly while symptoms persist | Due | PHQ-9 14 at intake during heavy drinking; repeat at four weeks |
| Survey | Suicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the rifle stored with her friend; 988 card carried |
| Self-management | Peer recovery support and mutual-help meetings | Weekly peer contact; meetings of her choice | Completed today | Met the peer recovery specialist once; considering a women's meeting |
| Self-management | Housing, food, income and health coverage | Every visit | Completed today | Medicaid and SNAP applications submitted with the community health worker |
| Self-management | Chewing tobacco | Every visit | Completed today | Chewing tobacco daily; not ready to stop |
| Medication safety | Naloxone | Reassess at every visit | Not indicated | No opioid use, and the urine test showed no opioids or fentanyl |
| Referral | Addiction medicine consultation | At the start of treatment | Completed today | Seen by Dr. Two Bulls-Harmon today |

## Goal progress

- Finish withdrawal safely at home without a seizure or delirium. Outcome by 2026-03-09: Five days of gabapentin with daily nurse checks; CIWA-Ar 9 at intake, 10 at most, 2 at one week; no seizure, hallucinations or confusion. **S**
- No drinking, her goal, with a medicine for alcohol use disorder. In progress; target 2026-06-22. **S**
- Liver tests back to normal and a clear answer on liver scarring. In progress; target 2026-06-22. **S**
- Regular meals and a healthier weight. In progress; target 2026-06-22. **S**
- A room of her own and health coverage. In progress; target 2026-06-22. **S**
- PHQ-9 below 10, and reassessment once she has stopped drinking. In progress; target 2026-05-11. **S**

## Medication changes

- Started: Naltrexone 50 mg oral tablet, one tablet daily **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (American Journal of Psychiatry 2018;175(1):86-90)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine 2020;14(3S Suppl 1):1-72)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology 2020;71(1):306-333)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Four-week review in three weeks with blood tests, PEth, elastography and the PHQ-9. Weekly peer contact. Call the clinic, the peer specialist or 988 if needed. **S**
- Next scheduled visit 2026-03-30: four-week review: naltrexone and the change to a monthly injection, liver stiffness, mood after four weeks without alcohol, and benefits. **S**
